BIOMAT Database Logo BIOMAT Database Logo

Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections. 1985

E A Swabb, and S A Jenkins, and J G Muir

Aztreonam was administered to a total of 681 patients with urinary tract infections due to susceptible gram-negative bacteria; 56 patients received a single 1-g intramuscular dose for acute uncomplicated cystitis, and 625 patients received multiple parenteral doses (usually a five-day course of 1 g two or three times daily) for a variety of urinary tract infections, including pyelonephritis, cystitis, prostatitis, and epididymitis. Microbiologic cure was achieved in 84% of patients in the single-dose study and in 85% of patients in the multiple-dose studies. In the latter studies the microbiologic cure rates for infections with Escherichia coli, the Klebsiella-Enterobacter-Serratia group, and Pseudomonas aeruginosa were 87%, 90%, and 76%, respectively. In a comparative study of aztreonam and cefamandole, the overall microbiologic cure rates were 89% and 80%, respectively. Of the 625 patients receiving multiple-dose therapy, 149 had urinary tract infections due to multiply drug-resistant bacteria; among these patients the microbiologic cure rate was 93%. Aztreonam constitutes effective therapy for urinary tract infections due to susceptible gram-negative bacilli.

UI MeSH Term Description Entries
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002435 Cefamandole Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate. Cephamandole,Compound 83405
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001398 Aztreonam A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. Az-threonam,Azactam,Azthreonam,SQ-26,776,Urobactam,Az threonam,SQ 26,776,SQ26,776
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases

Related Publications

E A Swabb, and S A Jenkins, and J G Muir
Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections.
January 1985, Reviews of infectious diseases,
E A Swabb, and S A Jenkins, and J G Muir
[Clinical efficacy of aztreonam in patients with complicated urinary tract infections].
December 1988, Hinyokika kiyo. Acta urologica Japonica,
E A Swabb, and S A Jenkins, and J G Muir
[Clinical experimentation with aztreonam in infections of the urinary tract].
January 1986, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
E A Swabb, and S A Jenkins, and J G Muir
[Aztreonam in urinary tract infections].
June 1986, La Clinica terapeutica,
E A Swabb, and S A Jenkins, and J G Muir
Clinical experience with aztreonam in urinary and respiratory tract infections.
January 1984, Current medical research and opinion,
E A Swabb, and S A Jenkins, and J G Muir
Treatment of urinary tract infections with aztreonam.
November 1985, The Journal of antimicrobial chemotherapy,
E A Swabb, and S A Jenkins, and J G Muir
Design of clinical trials in patients with urinary tract infections.
January 1992, Infection,
E A Swabb, and S A Jenkins, and J G Muir
[Clinical reevaluation of aztreonam (AZT) on urinary tract infections].
April 1989, Hinyokika kiyo. Acta urologica Japonica,
E A Swabb, and S A Jenkins, and J G Muir
Role of aztreonam in urinary tract infections.
June 1988, Urology,
E A Swabb, and S A Jenkins, and J G Muir
[Urinary tract infections. Summary].
May 1979, Lakartidningen,
Copied contents to your clipboard!